Last reviewed · How we verify
Oral Sedatives with or Without Analgesia
Oral sedatives with or without analgesia depress the central nervous system to reduce consciousness and/or pain perception.
Oral sedatives with or without analgesia depress the central nervous system to reduce consciousness, anxiety, and/or pain sensation. Used for Sedation and anxiolysis (with or without analgesia), Procedural sedation.
At a glance
| Generic name | Oral Sedatives with or Without Analgesia |
|---|---|
| Sponsor | Rocky Vista University, LLC |
| Drug class | CNS depressant (sedative/hypnotic ± analgesic) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | FDA-approved |
Mechanism of action
This category encompasses oral medications that act on the central nervous system through various mechanisms (e.g., GABAergic potentiation, opioid receptor agonism, or other CNS depressants) to induce sedation and potentially analgesia. The specific molecular targets depend on the individual agent(s) included in the formulation, which is not specified here.
Approved indications
- Sedation (with or without analgesia) for procedural or clinical use
Common side effects
- Respiratory depression
- Drowsiness
- Dizziness
- Nausea
- Dependence/tolerance
Key clinical trials
- Mode of Sedation During Endovascular Treatment of Vertebrobasilar Stroke (NA)
- Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome (PHASE4)
- Oral Sedation in Vitreoretinal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: